Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
Rhea-AI Summary
Teva (NYSE: TEVA) published its 2025 Healthy Future Report highlighting sustainability and access-to-medicine achievements, including meeting all sustainability-linked bond targets totaling about $7.5 billion.
Key metrics: nearly 8 million people reached via product donations; 39% reduction in Scope 1–2 GHG since 2019; 32% reduction in Scope 3 since 2020; $36.4 billion in healthcare savings from generics across 21 countries; and >99% employee compliance training completion.
Positive
- All sustainability-linked bond targets met across ~$7.5B of 2021/2023 issuances
- 39% reduction in Scope 1 and 2 GHG emissions since 2019
- 32% reduction in Scope 3 GHG emissions since 2020
- Nearly 8 million people reached through product donations
- $36.4 billion in healthcare savings from generics in 2025 across 21 countries
- >99% of active employees completed annual compliance and ethics training
Negative
- Scope 3 emissions represent approximately 90% of total GHG footprint
- Only 66% of significant suppliers (by spend) underwent sustainability evaluations
News Market Reaction – TEVA
In the Apr 30 session, TEVA declined 0.88%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.
- Through its global access to medicines programs, Teva reached nearly 8 million people through product donations around the world.
39% reduction in Teva’s Scope 1 and 2 GHG emissions since 2019 and32% reduction in Scope 3 GHG emissions since 2020—exceeding25% reduction targets.- More than
99% of active employees completed compliance and ethics training. - Teva’s generic medicines contributed
$36.4 billion in savings for healthcare systems across 21 countries.
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustainability targets, which are focused on the issues most relevant to its business, patients and the planet. Teva surpassed all 2025 targets associated with its sustainability-linked bonds—totaling approximately
“Advancing sustainability is fundamental to how we operate at Teva,” said Richard Francis, Teva’s President and CEO. “Our 2025 Healthy Future Report shows how we’re building the future we want to see—addressing global challenges by using our footprint, resources and skills to drive meaningful impact for our business and stakeholders.”
Healthy People
Teva operates eight access to medicines programs focused on delivering life-changing treatments to underserved populations. Several programs incorporate health system strengthening and capacity-building components, reflecting a holistic approach to improving health outcomes. Through these efforts, Teva reached nearly 8 million people with product donations and approximately 399,000 people through health system strengthening initiatives worldwide.
Healthy Planet
Teva reduced greenhouse gas (GHG) emissions from its operations (Scopes 1 and 2) by
Healthy Business
Teva continues to uphold strong standards for responsible and ethical practices across its operations, including its supply chain. The Company evaluated
Teva's generic medicines portfolio delivers substantial savings for healthcare systems, expanding patient access to essential medicines and strengthening the long-term sustainability of care. In 2025, Teva’s generic medicines contributed
Teva continues to be recognized and was ranked in the top
By embedding sustainability priorities throughout its operations, Teva is strengthening its resilience while working towards a healthy future for people and the planet.
Read the full 2025 Healthy Future Report to learn more.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical Company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| Teva Media Inquiries | TevaCommunicationsNorthAmerica@tevapharm.com |
| Teva Investor Relations Inquiries | TevaIR@Tevapharm.com |
